Imaging in Stem Cell Transplant and Cell-based Therapy

16 4

Table 10.2

(continued)

In vivo studiesDisease model

Mode of administration

Animal model

Outcome

References

Clinical trials

Disease condition

Cell type used

No. of patients enrolled

Route of administration

No. of cells administered

Outcome

References

Multiple sclerosis

ERCs

4

Intravenous and intrathecal

16–30 × 10

6

No immunological reactions or adverse side effect on 1 year follow up

[^58

]

DMD

ERCs

1

Intramuscular

116 × 10

6

↑ Muscle strength and

↓ respiratory

infection on 3 year follow-up

[^59

]

Ischemic cardiomyopathy

Allogeneic CD34 cells + ERCs

1

Intravenous

15 × 10

6

No mass formation, inflammation. EF increased from 30% to 40%,

↓ basic

natriuretic peptide values

[^60

]

K.G. Aghila Rani and T. Madan